TMPRSS2 and prostate cancer: ERG expression was later examined in samples of fusion-positive, androgen-dependent primary prostate cancers and CRPC samples, as well as in VCaP xenografts before and after castration, with the aim of establishing whether TMPRSS2:ERG fusion transcript expression is reactivated in CRPC after androgen deprivation therapy.